ABBVIE, INC. for ABBVIE INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Implementation of H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act) Draft legislation relating to economic activity in Puerto Rico
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Copyright/Patent/Trademark CPT
H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO S. 2554:Patient Right to Know Drug Prices Act - provisions related to notification of agreements to the FTC and DOJ
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Health Issues HCR
H.R. 4710: 340B Protecting Access for the Underserved and Safety-net Entities Act or PAUSE Act - Provisions related to the 340B program H.R. 5598: 340B Optimization Act - Provisions related to transparency in the 340B program H.R. 6071: SERV Communities Act - Provisions related to transparency in the 340B program S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 - Provisions related to drug pricing S. 2312: HELP Act - Provisions related to 340B program S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B program Drug cost and pricing policy issues Transparency policy issues Drug importation and counterfeiting policy issues 340B drug discount program policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| HAYDEN RHUDY KENNEDY | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Medicare/Medicaid MMM
H.R. 6642, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 - Provisions related to increases in the wholesale acquisition costs of prescription drugs Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Transparency policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Final Rule; Calendar Year (CY) 2018 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule with comment period (CMS-1678-FC) - Revisions to the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018 Proposed Rule: Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program (CMS-4182-P) CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| HAYDEN RHUDY KENNEDY | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Budget/Appropriations BUD
H.R.6157: Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.